We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors (RIFTOS MKI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02303444
Recruitment Status : Recruiting
First Posted : December 1, 2014
Last Update Posted : December 25, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of the study is to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

Condition or disease Intervention/treatment
Thyroid Neoplasms Drug: Sorafenib (Nexavar, BAY43-9006) Drug: Other Multikinase inhibitors

Detailed Description:
The primary objective of this study is to compare time to symptomatic progression (TTSP) from study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry with that of asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry.

Study Design

Study Type : Observational
Estimated Enrollment : 700 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
Actual Study Start Date : April 8, 2015
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : July 31, 2020

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
MKI patients
Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
Drug: Sorafenib (Nexavar, BAY43-9006)
Patients can get sorafenib at any time during study.
Drug: Other Multikinase inhibitors
Patients can get MKIs at any time during study.
non-MKI patients
Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
Drug: Sorafenib (Nexavar, BAY43-9006)
Patients can get sorafenib at any time during study.
Drug: Other Multikinase inhibitors
Patients can get MKIs at any time during study.


Outcome Measures

Primary Outcome Measures :
  1. Time to symptomatic progression (TTSP) from study entry [ Time Frame: Up to 6 years ]
    TTSP is defined as the time interval from the day of study entry to the date of first symptomatic progression. Patients who do not have a symptomatic progression at the time of analysis will be censored at the date of their last evaluable assessment.


Secondary Outcome Measures :
  1. Overall survival (OS) from time of study entry [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of study entry to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  2. Progression free survival (PFS) from time of study entry [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of study entry to date of first progression or death due to any cause, whichever comes first. The actual date of tumor assessments will be used for this calculation. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  3. OS from time of being diagnosed as radioactive iodine (RAI) refractory [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of being diagnosed as RAI refractory to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  4. Post-progression survival (PPS) from time of symptomatic progression [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of symptomatic progression to death due to any cause. Patients without symptomatic progression will be excluded from analysis and patients who are alive at the time of analysis will be censored at the last date when they were known to be alive.

  5. OS from initiation of the first Multikinase Inhibitor (MKI) [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of the first MKI to death due to any cause. Patients alive at the time of analysis will be censored at the last date when they were known to be alive.

  6. PFS from initiation of first MKI [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of first MKI to date of first progression or death due to any cause, whichever comes first. The actual date of tumor assessments will be used for this calculation. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  7. OS from initiation of any systemic treatment regimen [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of start of any systemic treatment regimen to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  8. PFS from initiation of any systemic treatment regimen [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of start of any systemic treatment regimen to date of first progression or death due to any cause, whichever comes first. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  9. Duration of each systemic treatment regimen [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of a treatment to the date of permanent discontinuation of a treatment (regardless of the reason for discontinuation including death). It includes interruption or drug holiday.

  10. Response assessment to each systemic treatment regimen according to the categories "Complete Response", "Partial Response", "Stable Disease", "Clinical Progression", "Radiological Progression", and "Not evaluable at this visit" [ Time Frame: Up to 6 years ]
    In case of "Clinical Progression" the CRF will ask for the presence of specific symptoms.

  11. OS from initiation of sorafenib [ Time Frame: Up to 6 years ]
    Defined as the time interval from the day of start of sorafenib to death due to any cause. Patients alive at the time of analysis will be censored at the last date known to be alive.

  12. PFS from initiation of sorafenib [ Time Frame: Up to 6 years ]
    Defined as the time interval from the date of start of sorafenib to date of first progression or death due to any cause, whichever comes first. Patients without a progression or death will be censored at their last evaluable date of tumor evaluation.

  13. Daily dose of sorafenib per patient throughout the treatment period [ Time Frame: Up to 6 years ]
  14. Number of adverse events during treatment with sorafenib [ Time Frame: Up to 6 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Any setting that provides treatment for progressive asymptomatic RAI refractory DTC
Criteria

Inclusion Criteria:

  • Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and poorly differentiated carcinoma)
  • DTC refractory to RAI
  • Radiological progression and preferably according to RECIST 1.1
  • No symptoms due to DTC
  • >/=1cm diameter of lesion confirmed by radiological exam
  • Life expectancy of at least 6 months

Exclusion Criteria:

  • Plan to be treated according to a clinical trial protocol for intervention including a locoregional therapy or systemic therapy
  • Previous treatment with MKIs for advanced disease
  • Hospice patients
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02303444


Contacts
Contact: Bayer Clinical Trials Contact clinical-trials-contact@bayer.com

  Hide Study Locations
Locations
United States, Alabama
Recruiting
Birmingham, Alabama, United States
United States, California
Recruiting
Los Angeles, California, United States
Recruiting
Torrance, California, United States
United States, Colorado
Recruiting
Aurora, Colorado, United States
United States, District of Columbia
Recruiting
Washington, District of Columbia, United States
United States, Florida
Recruiting
Plantation, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
United States, Hawaii
Recruiting
Honolulu, Hawaii, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
United States, Louisiana
Recruiting
New Orleans, Louisiana, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
United States, Michigan
Recruiting
Ann Arbor, Michigan, United States
Not yet recruiting
Detroit, Michigan, United States
United States, New York
Recruiting
Bronx, New York, United States
Not yet recruiting
Stony Brook, New York, United States
United States, North Carolina
Recruiting
Durham, North Carolina, United States
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States
United States, Texas
Recruiting
Dallas, Texas, United States
United States, West Virginia
Not yet recruiting
Charleston, West Virginia, United States
Algeria
Recruiting
Multiple Locations, Algeria
Argentina
Recruiting
Multiple Locations, Argentina
Austria
Withdrawn
Multiple Locations, Austria
Brazil
Recruiting
Multiple Locations, Brazil
Denmark
Withdrawn
Multiple Locations, Denmark
Egypt
Recruiting
Multiple Locations, Egypt
France
Recruiting
Multiple Locations, France
Germany
Recruiting
Multiple Locations, Germany
Greece
Recruiting
Multiple Locations, Greece
India
Recruiting
Multiple Locations, India
Indonesia
Withdrawn
Multiple Locations, Indonesia
Israel
Terminated
Multiple Locations, Israel
Japan
Recruiting
Multiple Locations, Japan
Lebanon
Recruiting
Multiple Locations, Lebanon
Mexico
Recruiting
Multiple Locations, Mexico
Netherlands
Recruiting
Multiple Locations, Netherlands
Norway
Withdrawn
Multiple Locations, Norway
Philippines
Recruiting
Multiple Locations, Philippines
Russian Federation
Recruiting
Multiple Locations, Russian Federation
Saudi Arabia
Recruiting
Multiple Locations, Saudi Arabia
Spain
Recruiting
Multiple Locations, Spain
Sweden
Withdrawn
Multiple Locations, Sweden
Taiwan
Recruiting
Multiple Locations, Taiwan
Turkey
Recruiting
Multiple Locations, Turkey
United Arab Emirates
Not yet recruiting
Multiple Locations, United Arab Emirates
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02303444     History of Changes
Other Study ID Numbers: 17852
NX1401 ( Other Identifier: Company internal )
First Posted: December 1, 2014    Key Record Dates
Last Update Posted: December 25, 2017
Last Verified: December 2017

Keywords provided by Bayer:
Progressive radioactive iodine refractory differentiated thyroid carcinoma

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Sorafenib
Iodine
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs